Refine
Year of publication
Document Type
- Preprint (741)
- Article (569)
- Conference Proceeding (3)
- Working Paper (1)
Has Fulltext
- yes (1314) (remove)
Is part of the Bibliography
- no (1314)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron Scattering (14)
- Hadron-Hadron scattering (experiments) (11)
- LHC (10)
- Heavy-ion collision (6)
- Jets (6)
- HIV (5)
- ALICE experiment (4)
- Collective Flow (4)
- Heavy Ions (4)
Institute
- Physik (1200)
- Frankfurt Institute for Advanced Studies (FIAS) (1061)
- Informatik (1023)
- Medizin (74)
- Geowissenschaften (12)
- Biochemie und Chemie (7)
- Biowissenschaften (5)
- Institut für Ökologie, Evolution und Diversität (4)
- ELEMENTS (3)
- Informatik und Mathematik (3)
The SU(3)-flavor violating decay J/ψ→Ξ(1530)−Ξ¯++c.c. is studied using (1310.6±7.0)×106 J/ψ events collected with the BESIII detector at BEPCII and the branching fraction is measured to be B(J/ψ→Ξ(1530)−Ξ¯++c.c.) = (3.17±0.02stat.±0.08syst.)×10−4. This is consistent with previous measurements with an improved precision. The angular parameter for this decay is measured for the first time and is found to be α=−0.21±0.04stat.±0.06syst.. In addition, we report evidence for the radiative decay Ξ(1530)−→γΞ− with a significance of 3.9σ, including the systematic uncertainties. The 90\% confidence level upper limit on the branching fraction is determined to be B(Ξ(1530)−→γΞ−)≤3.7\%.
We report a measurement of the observed cross sections of e+ e− → J/ψX based on 3.21 fb − 1 of data accumulated at energies from 3.645 to 3.891 GeV with the BESIII detector operated at the BEPCII collider. In analysis of the cross sections, we measured the decay branching fractions of B(ψ(3686) → J/ψX) = (64.4 ± 0.6 ± 1.6)% and B(ψ(3770) → J/ψX) = (0.5 ± 0.2 ± 0.1)% for the first time. The energy-dependent line shape of these cross sections cannot be well described by two Breit-Wigner (BW) amplitudes of the expected decays ψ (3686) → J/ψX and ψ(3770) → J/ψX. Instead, it can be better described with one more BW amplitude of the decay R(3760)→ J/ψX. Under this assumption, we extracted the R (3760) mass M R (3760 ) = 3766.2 ± 3.8 ± 0.4 MeV/c2, total width Γ tot R ( 3760 ) = 22.2 ± 5.9 ± 1.4 MeV, and product of leptonic width and decay branching fraction
ΓeeR(3760) B[R(3760) → J/ψX] = (79.4 ± 85.5 ± 11.7) eV. The significance of the R(3760) is 5.3σ. The first uncertainties of these measured quantities are from fits to the cross sections and second systematic.
Using a total of 9.0 fb−1 of e+e− collision data with center-of-mass energies between 4.15 and 4.30 GeV collected by the BESIII detector, we search for the processes e+e−→γX(3872) with X(3872)→π0χcJ for J=0,1,2. We report the first observation of X(3872)→π0χc1, a new decay mode of the X(3872), with a statistical significance of more than 5σ. Normalizing to the previously established process e+e−→γX(3872) with X(3872)→π+π−J/ψ, we find B(X(3872)→π0χc1)/B(X(3872)→π+π−J/ψ)=0.88+0.33−0.27±0.10, where the first error is statistical and the second is systematic. We set 90% confidence level upper limits on the corresponding ratios for the decays to π0χc0 and π0χc2 of 19 and 1.1, respectively.
The cross sections of the process e+e−→K0SK0L are measured at fifteen center-of-mass energies s√ from 2.00 to 3.08 GeV with the BESIII detector at the Beijing Electron Positron Collider (BEPCII). The results are found to be consistent with those obtained by BaBar. A resonant structure around 2.2 GeV is observed, with a mass and width of 2273.7±5.7±19.3 MeV/c2 and 86±44±51 MeV, respectively, where the first uncertainties are statistical and the second ones are systematic. The product of its radiative width (Γe+e−) with its branching fraction to K0SK0L (BrK0SK0L) is 0.9±0.6±0.7 eV.
Based on 14.7 fb−1 of e+e− annihilation data collected with the BESIII detector at the BEPCII collider at 17 different center-of-mass energies between 3.7730 GeV and 4.5995 GeV, Born cross sections of the two processes e+e−→pp¯η and e+e−→pp¯ω are measured for the first time. No indication of resonant production through a vector state V is observed, and upper limits on the Born cross sections of e+e−→V→pp¯η and e+e−→V→pp¯ω at the 90% confidence level are calculated for a large parameter space in resonance masses and widths. For the current world average parameters of the ψ(4230) of m=4.2187 GeV/c2 and Γ=44 MeV, we find upper limits on resonant production of the pp¯η and pp¯ω final states of 7.5 pb and 10.4 pb at the 90% CL, respectively.
Measurements of the branching fractions for D⁺ → Kₛ⁰Kₛ⁰K⁺, Kₛ⁰Kₛ⁰π⁺ and D⁰ → Kₛ⁰Kₛ⁰, Kₛ⁰Kₛ⁰Kₛ⁰
(2016)
By analyzing 2.93 fb−1 of data taken at the ψ(3770) resonance peak with the BESIII detector, we measure the branching fractions for the hadronic decays D+→K0SK0SK+, D+→K0SK0Sπ+, D0→K0SK0S and D0→K0SK0SK0S. They are determined to be B(D+→K0SK0SK+)=(2.54±0.05stat.±0.12sys.)×10−3, B(D+→K0SK0Sπ+)=(2.70±0.05stat.±0.12sys.)×10−3, B(D0→K0SK0S)=(1.67±0.11stat.±0.11sys.)×10−4 and B(D0→K0SK0SK0S)=(7.21±0.33stat.±0.44sys.)×10−4, where the second one is measured for the first time and the others are measured with significantly improved precision over the previous measurements.
Measurements of the branching fractions for D⁺ → Kₛ⁰Kₛ⁰K⁺, Kₛ⁰Kₛ⁰π⁺ and D⁰ → Kₛ⁰Kₛ⁰, Kₛ⁰Kₛ⁰Kₛ⁰
(2016)
By analyzing 2.93 fb−1 of data taken at the ψ(3770) resonance peak with the BESIII detector, we measure the branching fractions for the hadronic decays D+→K0SK0SK+, D+→K0SK0Sπ+, D0→K0SK0S and D0→K0SK0SK0S. They are determined to be B(D+→K0SK0SK+)=(2.54±0.05stat.±0.12sys.)×10−3, B(D+→K0SK0Sπ+)=(2.70±0.05stat.±0.12sys.)×10−3, B(D0→K0SK0S)=(1.67±0.11stat.±0.11sys.)×10−4 and B(D0→K0SK0SK0S)=(7.21±0.33stat.±0.44sys.)×10−4, where the second one is measured for the first time and the others are measured with significantly improved precision over the previous measurements.
Background: 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC.
Methods: This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial with a sample size of 159 patients from 20 centers in 3 countries. Patients with stage IV colorectal adenocarcinoma limited to liver metastases are included. Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous metastases, eligible patients are randomized 2:1 to receive either L-BLP25 or placebo. Those allocated to L-BLP25 receive a single dose of 300 mg/m2 cyclophosphamide (CP) 3 days before first L-BLP25 dose, then primary treatment with s.c. L-BLP25 930 mug once weekly for 8 weeks, followed by s.c. L-BLP25 930 mug maintenance doses at 6-week (years 1&2) and 12-week (year 3) intervals unless recurrence occurs. In the control arm, CP is replaced by saline solution and L-BLP25 by placebo. Primary endpoint is the comparison of recurrence-free survival (RFS) time between groups. Secondary endpoints are overall survival (OS) time, safety, tolerability, RFS/OS in MUC-1 positive cancers. Exploratory immune response analyses are planned. The primary endpoint will be assessed in Q3 2016. Follow-up will end Q3 2017. Interim analyses are not planned.
Discussion: The design and implementation of such a vaccination study in colorectal cancer is feasible. The study will provide recurrence-free and overall survival rates of groups in an unbiased fashion. Trial Registration EudraCT Number 2011-000218-20
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric junction.
Methods: Patients received neoadjuvant radiotherapy (50.4 Gy) together with weekly docetaxel (20 mg/m2 at dose level (DL) 1 and 2, 25 mg/m2 at DL 3) and oxaliplatin (40 mg/m2 at DL 1, 50 mg/m2 at DL 2 and 3) over 5 weeks. The primary endpoint was the DLT and the MTD of the RCT regimen. Secondary endpoints included overall response rate (ORR) and progression-free survival (PFS).
Results: A total of 24 patients were included. Four patients were treated at DL 1, 13 patients at DL 2 and 7 patients at DL 3. The MTD of the RCT was considered DL 2 with docetaxel 20 mg/m2 and oxaliplatin 50 mg/m2. Objective response (CR/PR) was observed in 32% (7/22) of patients. Eighteen patients (75%) underwent surgery after RCT. The median PFS for all patients (n = 24) was 6.5 months. The median overall survival for all patients (n = 24) was 16.3 months. Patients treated at DL 2 had a median overall survival of 29.5 months.
Conclusion: Neoadjuvant RCT with docetaxel 20 mg/m2 and oxaliplatin 50 mg/m2 was effective and showed a good toxicity profile. Future studies should consider the addition of targeted therapies to current neoadjuvant therapy regimens to further improve the outcome of patients with advanced cancer of the oesophagogastric junction.
Trial Registration: NCT00374985
Background: Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly attributable to co-infection with hepatitis B or C. The impact of other risk factors, including prolonged exposure to combined antiretroviral therapy (cART) is poorly understood. Our aim was to determine the prevalence of liver fibrosis and associated risk factors in HIV-infected individuals based on non-invasive fibrosis assessment using transient elastography (TE) and serum biomarkers (Fibrotest [FT]).
Methods: In 202 consecutive HIV-infected individuals (159 men; mean age 47 ± 9 years; 35 with hepatitis-C-virus [HCV] co-infection), TE and FT were performed. Repeat TE examinations were conducted 1 and 2 years after study inclusion.
Results: Significant liver fibrosis was present in 16% and 29% of patients, respectively, when assessed by TE (≥ 7.1 kPa) and FT (> 0.48). A combination of TE and FT predicted significant fibrosis in 8% of all patients (31% in HIV/HCV co-infected and 3% in HIV mono-infected individuals). Chronic ALT, AST and γ-GT elevation was present in 29%, 20% and 51% of all cART-exposed patients and in 19%, 8% and 45.5% of HIV mono-infected individuals. Overall, factors independently associated with significant fibrosis as assessed by TE (OR, 95% CI) were co-infection with HCV (7.29, 1.95-27.34), chronic AST (6.58, 1.30-33.25) and γ-GT (5.17, 1.56-17.08) elevation and time on dideoxynucleoside therapy (1.01, 1.00-1.02). In 68 HIV mono-infected individuals who had repeat TE examinations, TE values did not differ significantly during a median follow-up time of 24 months (median intra-patient changes at last TE examination relative to baseline: -0.2 kPa, p = 0.20).
Conclusions: Chronic elevation of liver enzymes was observed in up to 45.5% of HIV mono-infected patients on cART. However, only a small subset had significant fibrosis as predicted by TE and FT. There was no evidence for fibrosis progression during follow-up TE examinations.